GSK begins patient dosing in phase 3 trial of RSV maternal candidate vaccine

This article was originally published here

RSV is responsible for respiratory infections such as bronchiolitis and viral pneumonia in infants. It is estimated that in the world, 33 million cases of RSV occur in

The post GSK begins patient dosing in phase 3 trial of RSV maternal candidate vaccine appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply